Loading…
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-76M | $-74M | $-62M | -109.8% | -19.1% | 15.8% |
| 2024 | $0M | $-66M | $-64M | $-69M | -91.4% | -33.4% | 27.1% |
| 2023 | $0M | $-52M | $-50M | $-37M | -55.6% | -96.6% | 11.1% |
| 2022 | $10M | $-45M | $-45M | $-44M | -63.4% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 10.39 | 0.35 | 0.24 | 0.19 |
| Operating Revenue | - | 10.39 | 0.35 | 0.24 | 0.19 |
| Operating Expense | - | 56.79 | 55.27 | 68.15 | 77.82 |
| Research And Development | - | 42.81 | 42.29 | 54.37 | 60.22 |
| Selling General And Administration | - | 13.98 | 12.98 | 13.78 | 17.60 |
| Total Expenses | - | 56.79 | 55.27 | 68.15 | 77.82 |
| Operating Income | - | -46.40 | -54.92 | -67.91 | -77.63 |
| Total Operating Income As Reported | - | -46.40 | -54.92 | -67.91 | -77.63 |
| EBITDA | - | -44.71 | -52.18 | -66.37 | -76.07 |
| Normalized EBITDA | - | -44.71 | -52.18 | -66.37 | -76.07 |
| EBIT | - | -46.40 | -54.92 | -67.91 | -77.63 |
| Other Non Operating Income Expenses | - | 1.06 | 4.52 | 3.89 | 3.50 |
| Other Income Expense | - | 1.06 | 4.52 | 3.89 | 3.50 |
| Pretax Income | - | -45.34 | -50.40 | -64.02 | -74.12 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -45.34 | -50.40 | -64.02 | -74.12 |
| Net Income From Continuing And Discontinued Operation | - | -45.34 | -50.39 | -64.02 | -74.12 |
| Net Income From Continuing Operation Net Minority Interest | - | -45.34 | -50.39 | -64.02 | -74.12 |
| Net Income | - | -45.34 | -50.39 | -64.02 | -74.12 |
| Net Income Common Stockholders | - | -45.34 | -50.39 | -64.02 | -74.12 |
| Net Income Including Noncontrolling Interests | - | -45.34 | -50.40 | -64.02 | -74.12 |
| Normalized Income | - | -45.34 | -50.39 | -64.02 | -74.12 |
| Diluted NI Availto Com Stockholders | - | -45.34 | -50.39 | -64.02 | -74.12 |
| Basic Average Shares | 19.08 | 28.42 | 53.61 | 74.26 | - |
| Diluted Average Shares | 19.08 | 28.42 | 53.61 | 74.26 | - |
| Reconciled Depreciation | - | 1.70 | 2.74 | 1.54 | 1.55 |
| Minority Interests | - | 0 | 0.01 | 0 | 0 |
| General And Administrative Expense | - | 13.98 | 12.98 | 13.78 | 17.60 |
| Other Gand A | - | 13.98 | 12.98 | 13.78 | 17.60 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| aTyr Pharma, Inc.this co. | ATYR | $50M | -0.68 | 0.75 | -109.8% | -0.68 |
| LENSAR, Inc. | LNSR | $68M | -1.98 | -2.61 | 131.7% | -2.88 |
| DocGo Inc. | DCGO | $56M | -0.31 | 0.39 | -126.7% | -0.47 |
| Myomo, Inc. | MYO | $50M | -3.20 | 4.37 | -136.6% | -4.36 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $46M | -2.09 |
| - |
| - |
| - |
| - |
| - |
| 5.86 |
| -280.5% |
| - |
| Accuray Incorporated | ARAY | $43M | -27.33 | 0.54 | -2.0% | 8.03 |
| Gossamer Bio, Inc. | GOSS | $42M | -0.24 | -0.34 | 138.8% | -1.31 |
| Tevogen Bio Holdings Inc. | TVGN | $41M | -1.57 | -2.42 | 154.2% | -1.89 |
| INmune Bio Inc. | INMB | $36M | -0.78 | 1.53 | -195.3% | -0.40 |
| Peer Median | - | -1.78 | 0.46 | -64.3% | -1.31 | |